title: [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
abstract: We report 2 cases of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer successfully treated with a combination therapy of S-1, cisplatin( CDDP), and trastuzumab followed by curative resection. Case 1 involved a 62-year-old man with type 3 HER2-positive gastric cancer spanning the antrum of the stomach to the duodenal bulb and directly invading the pancreatic head( cT4b[ Panc] N3H0P0M0, Stage IIIC). We diagnosed it as an unresectable cancer, and selected S-1, CDDP, and trastuzumab for combination chemotherapy. S-1 (120 mg/body/day) was administered orally for 2 weeks, followed by 1 drug-free week as a course, and CDDP (60 mg/m2) and trastuzumab (8 mg/kg loading dose and 6 mg/kg maintenance) were administered by intravenous infusion on day 1. After the third course, significant tumor and lymph node reduction was observed; however, pyloric stenosis developed. Distal gastrectomy with D2 lymphadenectomy was performed. Case 2 involved a 62-year-old woman with type 4 HER2-positive gastric cancer from the angle of the stomach to the duodenal bulb and directly invading the pancreatic head (cT4b [Panc] N2H0P0M0, Stage IIIC). After the third course of combination therapy, significant tumor reduction and disappearance of lymph nodes metastasis was observed. We diagnosed the patient as having a resectable cancer, and performed distal gastrectomy with D2 lymphadenectomy.
authors.affiliation: Dept. of Surgery, Osaka Rosai Hospital.
authors.forename: Akinobu
authors.initials: A
authors.lastname: Yasuyama
authors.forename: Shoki
authors.initials: S
authors.lastname: Mikata
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Soma
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Chikashi
authors.initials: C
authors.lastname: Watase
authors.forename: Michiyo
authors.initials: M
authors.lastname: Kubota
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Matsuura
authors.forename: Ho Min
authors.initials: HM
authors.lastname: Kim
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Masaki
authors.initials: M
authors.lastname: Hirota
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Morishima
authors.forename: Nobuki
authors.initials: N
authors.lastname: Matsunami
authors.forename: Junichi
authors.initials: J
authors.lastname: Hasegawa
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miwa
authors.forename: Riichiro
authors.initials: R
authors.lastname: Nezu
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy* / Q000601:surgery; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D002945:Cisplatin; D004338:Drug Combinations; D010094:Oxonic Acid; D018719:Erb-b2 Receptor Tyrosine Kinases; D005641:Tegafur; D000068878:Trastuzumab; C079198:S 1 (combination); C508053:ERBB2 protein, human